MOLECULAR PARTNERS AG has a total of 131 patent applications. It decreased the IP activity by 81.0%. Its first patent ever was published in 2009. It filed its patents most often in United States, EPO (European Patent Office) and WIPO (World Intellectual Property Organization). Its main competitors in its focus markets pharmaceuticals, biotechnology and chemical engineering are ROCHE GLYCART AG, TEVA PHARMACEUTICALS AUSTRALIA PTY LTD and ABBVIE BIOTHERAPEUTICS INC.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 17 | |
#2 | EPO (European Patent Office) | 13 | |
#3 | WIPO (World Intellectual Property Organization) | 13 | |
#4 | Australia | 11 | |
#5 | China | 9 | |
#6 | Republic of Korea | 9 | |
#7 | Canada | 8 | |
#8 | Brazil | 7 | |
#9 | Israel | 6 | |
#10 | Mexico | 6 | |
#11 | Hong Kong | 4 | |
#12 | Chile | 3 | |
#13 | Russian Federation | 3 | |
#14 | Singapore | 3 | |
#15 | Argentina | 2 | |
#16 | Colombia | 2 | |
#17 | Japan | 2 | |
#18 | New Zealand | 2 | |
#19 | Philippines | 2 | |
#20 | South Africa | 2 | |
#21 | Hungary | 1 | |
#22 | India | 1 | |
#23 | Montenegro | 1 | |
#24 | Malaysia | 1 | |
#25 | Serbia | 1 | |
#26 | Taiwan | 1 | |
#27 | Uruguay | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Chemical engineering |
# | Technology | |
---|---|---|
#1 | Peptides | |
#2 | Medical preparations | |
#3 | Therapeutic chemical compounds | |
#4 | Microorganisms | |
#5 | Separation |
# | Name | Total Patents |
---|---|---|
#1 | Binz Hans Kaspar | 66 |
#2 | Forrer Patrik | 46 |
#3 | Stumpp Michael Tobias | 32 |
#4 | Dolado Ignacio | 32 |
#5 | Phillips Douglas | 29 |
#6 | Merz Frieder W | 28 |
#7 | Steiner Daniel | 24 |
#8 | Sonderegger Ivo | 24 |
#9 | Gulotti-Georgieva Maya | 23 |
#10 | Fiedler Ulrike | 22 |
Publication | Filing date | Title |
---|---|---|
WO2020245173A1 | Recombinant fap binding proteins and their use | |
UY38739A | MULTI-SPECIFIC PROTEINS | |
WO2020245175A1 | Recombinant 4-1bb binding proteins and their use | |
WO2020245171A1 | Designed ankyrin repeat domain with improved stability | |
KR20190050802A | Recombinant binding proteins and uses thereof | |
WO2016156596A1 | Designed ankyrin repeat domains with binding specificity for serum albumin | |
AU2014243418A1 | Modified binding proteins inhibiting the VEGF-A receptor interaction | |
US2016251404A1 | Designed ankyrin repeat proteins binding to hepatocyte growth factor | |
AU2013283296A1 | Designed ankyrin repeat proteins binding to platelet-derived growth factor | |
EP2738180A1 | Binding proteins comprising at least two binding domains against HER2. | |
CN103403024A | Improved N-terminal capping modules for designed ankyrin repeat proteins | |
AR081361A1 | MODIFIED UNION PROTEINS THAT INHIBIT THE RECEPTOR INTERACTION OF THE VASCULAR ENDOTELIAL GROWTH FACTOR FROM GLICOPROTEIN TO VEGF-A | |
MX359570B | Binding proteins inhibiting the vegf-a receptor interaction. |